Enhanced opens access to six HHS-listed peptides

Enhanced Group Inc. (NYSE: ENHA), a NYSE-listed telehealth and performance-products company, said on November 3, 2026, that eligible consumers can now get prescription access to six peptides through licensed clinicians on its Live Enhanced platform. The Business Wire release names BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, and says the move follows the Department of Health and Human Services policy announced on October 28, 2026.

The company said its existing peptide offering of GHK-Cu and sermorelin is now complemented by those six. All six are available by prescription only, after an individual evaluation by a licensed clinician, the release says. Enhanced does not claim FDA approval of any finished peptide drug.

What Enhanced says about how the peptides are supplied

Enhanced described the offering around clinical and pharmacy standards. Prescribing clinicians, it said, have completed training on the peptides and follow clinical protocols developed with Enhanced’s medical commission. Each peptide is compounded and dispensed by a state-licensed U.S. pharmacy, “in the forms and routes the policy permits, one peptide per preparation.” Active pharmaceutical ingredients, the company said, come from FDA-registered, CGMP-compliant manufacturers and are accompanied by certificates of analysis, with identity, purity and quality testing. Clinicians remain involved throughout treatment, according to the release.

Co-founder and CEO Maximilian Martin said:

“We believe the right way to grow in this category is with medical supervision by licensed clinicians, regulated pharmacies and quality-controlled ingredients.”

The company also wrote that FDA rulemaking on the 503A bulk drug substances list is ongoing, and that the advisory committee is expected to review additional peptides in February 2027. Enhanced said it may expand access if and as regulators act.

The HHS draft policy backdrop

HHS’s underlying document is a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” A notice of availability was published in the Federal Register on October 30, 2026, at 91 FR 68526-68527 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496), days before Enhanced’s launch (our report; GovInfo HTML).

Until a final rule addresses each substance on the 503A bulks list, HHS says it does not intend to take enforcement action against State-licensed pharmacies, Federal facilities or licensed physicians compounding Appendix A peptides — the same six Enhanced named — when listed conditions are met. The Federal Register notice states that compounded drugs are not FDA-approved, that the draft policy does not establish rights for any person and is not binding on HHS or the public, and that HHS may revisit the interim policy if a safety signal or product-quality issue arises. Written comments on the docket run for two weeks after publication; that window closes November 13, 2026.

Earlier positioning — and how peers framed access

On July 27, 2026, after the Pharmacy Compounding Advisory Committee’s July 23-24 vote recommending the same six substances for the 503A bulks list, Enhanced said it was positioned to offer newly compoundable peptides through Live Enhanced if FDA completed rulemaking. PCAC votes are advisory; formal inclusion still requires notice-and-comment rulemaking (our July coverage).

Other commercial responses after the October HHS notice have been more limited or staged. Hims & Hers on October 29 previewed Peptides+ and a waitlist, naming BPC-157 and TB-500 only “to follow when allowable” (our report). Superpower opened pre-orders and DataMeds’ Corexa unit described a supply-and-dispensing path for the six Appendix A peptides in the days that followed.

Why it matters

Enhanced is putting all six HHS Appendix A peptides on a named telehealth platform under clinician prescription and U.S. pharmacy compounding, days after the draft enforcement-discretion notice. That is a concrete commercial response from a listed company, not a final bulks-list rule and not FDA approval of finished peptide drugs. Whether pharmacies meet every listed HHS condition, how state boards treat telehealth protocols, and whether HHS revises the draft after the comment period remain open.

What is not known

• Which state-licensed pharmacy or pharmacies Enhanced is using, and in which states prescriptions will be filled.
• How Enhanced’s medical-commission protocols map onto each Appendix B identity and route limit in the HHS policy.
• Whether HHS will revise or withdraw the draft policy after the November 13 comment deadline, or before any February 2027 advisory-committee review.
• How demand, payers or competitors will respond once prescriptions begin flowing under the interim policy.

What to watch

Docket comments on HHS-OASH-2026-0496 through November 13; any FDA 503A bulks-list rulemaking steps under RIN 0910-ZD94; the advisory committee’s expected February 2027 peptide review; and further commercial launches that cite the same interim policy.